Idzerda NMA, et al. - Via a post-hoc analysis among 5,081 patients with type 2 diabetes mellitus partaking in the ALTITUDE trial, researchers investigated if N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the impact of supplemental therapy with aliskiren on cardio-renal endpoints. Compared to placebo, aliskiren led to reduction in the risk of the primary cardio-renal endpoint events by 20% and 2% in the two lowest NT-proBNP tertiles, and it increased the risk by 25% in the highest NT-proBNP tertile. They noted similar trends for the cardiovascular and ESRD endpoints. Thereby suggesting the potential utility of baseline NT-proBNP as a marker to predict the response to aliskiren on cardio-renal outcomes when added to standard therapy with RAAS inhibition.